AstraZeneca ends work on cardio drug; Lisata and Qilu terminate dealnews2026-01-27T14:31:24+00:00January 27th, 2026|Endpoints News|
Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listingnews2026-01-26T15:07:04+00:00January 26th, 2026|Endpoints News|
Erasca, Corvus, BioAge target $500M+ offeringsnews2026-01-22T14:43:32+00:00January 22nd, 2026|Endpoints News|
Tanabe pill delays blood disorder; enGene adds up to $100M from loansnews2026-01-21T16:25:30+00:00January 21st, 2026|Endpoints News|
Aspect Bio takes Novo castoff therapies; Takeda trims US jobsnews2026-01-20T14:58:33+00:00January 20th, 2026|Endpoints News|
Alfasigma gains neuro treatment; BridgeBio offers $550M in notesnews2026-01-15T15:48:35+00:00January 15th, 2026|Endpoints News|
ImmunityBio’s Anktiva lung cancer data; Glaukos’ glaucoma implant sales disappointnews2026-01-14T16:08:20+00:00January 14th, 2026|Endpoints News|
VantAI gets $80M and new name; Dynavax discloses it had pre-Sanofi suitornews2026-01-13T16:22:37+00:00January 13th, 2026|Endpoints News|
Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data reportnews2026-01-12T16:22:25+00:00January 12th, 2026|Endpoints News|
Venture firm a16z raises $700M; Ribo Life’s $230M Hong Kong IPOnews2026-01-09T16:26:48+00:00January 9th, 2026|Endpoints News|
